Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: A meta-analysis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5925-5932

  Fan, Xiao Liang ^a   Cai, Guo Ping ^b   Zhu, Liu Long ^a   Ding, Guo Ming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Ifosfamide; Meta analysis; Osteosarcoma

Indexed keywords

IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARDIOTOXICITY; CEREBELLUM DISEASE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEVER; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TOXICITY; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VOMITING; BONE NEOPLASMS; DISEASE FREE SURVIVAL; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; IFOSFAMIDE; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84946564814     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S91217     Document Type: Article

References (27)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973-989.
2. Bielack S, Jurgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009; 152: 289-308.
3. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989; 7: 126-131.
4. Jurgens H, Exner U, Kuhl J, et al. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol. 1989; 24 Suppl 1: S40-S44.
5. Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol. 1986; 18 Suppl2: S25-S28.
6. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 1191-1198.
7. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993; 71: 1898-1903.
8. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997; 33: 232-237.
9. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998; 16: 3628-3633.
10. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001; 19: 1818-1829.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
13. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001; 135: 982-989.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
19. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
20. Le Deley MC, Guinebretiere JM, Gentet JC, et al. SFOPOS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007; 43: 752-761.
21. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9): 2004-2011.
22. Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001; 27(1): 98-104.
23. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009; 115: 5339-5348.
24. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 633-638.
25. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694-701.
26. Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012; 30: 2112-2118.
27. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26: 4385-4393.